1. Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients
    Feng Yang-Chun et al, 2017, Medicine CrossRef
  2. Nivolumab für das vorbehandelte metastasierte Analkarzinom
    Daniel Martin et al, 2018, Strahlenther Onkol CrossRef
  3. Nivolumab für das vorbehandelte metastasierte Analkarzinom
    Daniel Martin et al, 2018, Info Onkol. CrossRef
  4. null
    Olga Kurmyshkina et al, 2018 CrossRef
  5. Nivolumab für das vorbehandelte metastasierte Analkarzinom
    Daniel Martin et al, 2018, Gastro-News CrossRef
  6. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
    Peixin Dong et al, 2018, Front Oncol CrossRef
  7. The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers
    S. Otter et al, 2018, Clinical Oncology CrossRef
  8. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy
    Franz Rödel et al, 2018, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  9. PD-1/PD-L1 Inhibitors in Cervical Cancer.
    Yuncong Liu et al, 2019, Front Pharmacol CrossRef
  10. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
    Yumeng Wang et al, 2019, Front. Med. CrossRef
  11. Aberrant PD1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection
    Tianying Wang et al, 2019, Antiviral Research CrossRef
  12. P16 expression and its association with PD-L1 expression and FOXP3-positive tumor infiltrating lymphocytes in head and neck squamous cell carcinoma
    Taeyeong Kim et al, 2019, Mol. Cell. Toxicol. CrossRef
  13. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies
    Kathy Pan et al, 2019, Targ Oncol CrossRef
  14. Pharmacodynamics of current and emerging treatments for cervical cancer
    Alfonso Duenas-Gonzalez et al, 2019, Expert Opinion on Drug Metabolism & Toxicology CrossRef
  15. CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression
    Joseph A. Westrich et al, 2019, Oncogene CrossRef
  16. Effect of Radical Surgery for Advanced Adenocarcinoma of Esophagogastric Junction on Perioperative Cellular Cell Immunity
    Shou-miao Li et al, 2019, Journal of Investigative Surgery CrossRef
  17. Immunotherapy for Uterine Cervical Cancer
    Masahiro Kagabu et al, 2019, Healthcare CrossRef
  18. Radiobiology: Foundation and New Insights in Modeling Brachytherapy Effects
    Pierre Annede, MD, MSc et al, 2020, Seminars in Radiation Oncology CrossRef
  19. Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects
    Mine Özcan-Wahlbrink et al, 2019, Front. Immunol. CrossRef
  20. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
    Hongning Cai et al, 2020, Biomed Pharmacother CrossRef
  21. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
    Masahiro Kagabu et al, 2020, IJMS CrossRef
  22. The roles of programmed death ligand 1 in virus-associated cancers
    Morvarid Golrokh Mofrad et al, 2020, Infection, Genetics and Evolution CrossRef
  23. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
    Yun Liang et al, 2020, Diagn Pathol CrossRef
  24. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions
    Soumaya Allouch et al, 2020, Front. Oncol. CrossRef
  25. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
    Nora Wuerdemann et al, 2020, IJMS CrossRef
  26. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer
    Nicoletta D’Alessandris et al, 2020, Virchows Arch CrossRef
  27. Molecular Oncology of Gynecologic Tumors
    Isabel Alvarado-Cabrero, 2020, Archives of Medical Research CrossRef

  28. Therapeutic Vaccines for HPV-Associated Malignancies


    Claire Smalley Rumfield et al, 2020, ITT CrossRef
  29. The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature
    Lennox Chitsike et al, 2020, Curr. Treat. Options in Oncol. CrossRef
  30. Current scenario of biomarkers in cervical cancer and oncogenesis by HPV
    Luciane Rocha Ernlund Pangracio et al, 2019, J Bras Doenças Sex Transm CrossRef
  31. Lectin-Like Transcript 1 (LLT1) Checkpoint: A Novel Independent Prognostic Factor in HPV-Negative Oropharyngeal Squamous Cell Carcinoma
    Mario Sanchez-Canteli et al, 2020, Biomedicines CrossRef
  32. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Shiwen Peng et al, 2021, mBio CrossRef
  33. The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists
    Tjalling Bosse et al, 2021 CrossRef
  34. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
    Yannick Verhoeven et al, 2021, IJMS CrossRef
  35. PD-L1 Expression in Endocervical Adenocarcinoma
    Glorimar Rivera-Colon et al, 2021 CrossRef
  36. Immunotherapy for HPV Malignancies
    Maxwell Y. Lee et al, 2021, Seminars in Radiation Oncology CrossRef
  37. Modern possibilities of using immunotherapy in the treatment of cervical cancer
    A. V. Tarasova et al, 2021, Opuholi ženskoj reproduktivnoj sistemy CrossRef
  38. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
    Lili Chen et al, 2022, Histopathology CrossRef
  39. Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma
    Fang Wen et al, 2021, Front. Med. CrossRef
  40. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer.
    Maximilian Fleischmann et al, 2021, Cancers (Basel) CrossRef
  41. IFN‐γ‐induced PD‐L1 expression on human melanocytes is impaired in vitiligo
    Marcella Willemsen et al, 2021, Exp Dermatol CrossRef
  42. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
    Alejandro Olivares-Hernández et al, 2021, Life CrossRef
  43. Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers
    Miaomiao Ye et al, 2022, Molecular Therapy - Oncolytics CrossRef
  44. 1α,25(OH)2D3(VD3) promotes Raddeanin A-induced anti-proliferative effects on HeLa cell apoptosis and autophagy through negative regulation of HPV18E6-E7/PD-L1/VDR axis
    Zhiyu Li et al, 2022, Bioengineered CrossRef
  45. T cell subtype profiling measures exhaustion and predicts anti-PD-1 response
    Ian Schillebeeckx et al, 2022, Sci Rep CrossRef
  46. Advances in Radiation Oncology for the Treatment of Cervical Cancer
    Mame Daro Faye et al, 2022, Current Oncology CrossRef
  47. The Prognostic Values of HPV Genotypes and Tumor PD-L1 Expression in Patients With HPV-associated Endocervical Adenocarcinoma
    Feng Zhou et al, 2022 CrossRef
  48. Tumor Immunity and Immunotherapy for HPV-Related Cancers
    Achraf A. Shamseddine et al, 2021 CrossRef
  49. New Treatment Options for Cervical Cancer
    Lucie Mouková, 2021, Onkologie CrossRef
  50. Current and future direction in treatment of HPV-related cervical disease
    Niloofar Khairkhah et al, 2022, J Mol Med CrossRef
  51. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer
    Na Li et al, 2022, Cellular Signalling CrossRef
  52. Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, “I Am like a Box of Complexity, You Never Know What You Are Gonna Get”
    Ehsan Soleymaninejadian et al, 2022, Vaccines CrossRef
  53. Immune Checkpoint Inhibitors in the Treatment of Cancer
    Wissam Zam et al, 2022, CRCEP CrossRef
  54. Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?
    Coriolan Lebreton et al, 2022 CrossRef
  55. Monoclonal antibodies in cervical malignancy-related HPV
    Parisa Shiri Aghbash et al, 2022, Front. Oncol. CrossRef
  56. Current understanding of epigenetics role in melanoma treatment and resistance
    Mohsen Karami Fath et al, 2022, Cancer Cell Int CrossRef
  57. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice
    Shiwen Peng et al, 2022, J Biomed Sci CrossRef
  58. PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
    Weijia Huang et al, 2022, Front. Oncol. CrossRef
  59. null
    Kei Kawana, 2022 CrossRef
  60. Immune checkpoint inhibitors in cervical cancer: Current status and research progress
    Yunkai Xie et al, 2022, Front. Oncol. CrossRef
  61. The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer
    Eva K. Egger et al, 2023, Cancers CrossRef
  62. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
    Blair McNamara et al, 2023, Expert Opinion on Biological Therapy CrossRef
  63. A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities
    Jonathan Peña Avila et al, 2023, Cancers CrossRef
  64. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
    Hao-Yu Liang et al, 2023, J Med Virol CrossRef
  65. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
    PARISA SHIRI AGHBASH et al, 2022 CrossRef
  66. Advances in the application of immune checkpoint inhibitors in gynecological tumors
    YingGang Zou et al, 2023, International Immunopharmacology CrossRef
  67. Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
    Jusheng An et al, 2023, Front. Immunol. CrossRef
  68. De novo design of protein interactions with learned surface fingerprints
    Pablo Gainza et al, 2023, Nature CrossRef
  69. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
    Mary L Disis et al, 2023, J Immunother Cancer CrossRef
  70. Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
    Sandhya Sharma et al, 2020, Curr Stem Cell Rep CrossRef
  71. TIME Is Ticking for Cervical Cancer
    Vijay Kumar et al, 2023, Biology CrossRef
  72. Single‐cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment
    Guangxu Cao et al, 2023, The EMBO Journal CrossRef
  73. Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances
    Angel Chao et al, 2023, Biomedical Journal CrossRef
  74. The programed death‐1/programed death ligand‐1 axis and its potential as a therapeutic target for virus‐associated tumours
    Jing Li et al, 2023, Reviews in Medical Virology CrossRef
  75. Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
    Shuping Yin et al, 2023, Biomedicine & Pharmacotherapy CrossRef
  76. Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer
    Yang Li et al, 2023, Technol Cancer Res Treat CrossRef
  77. Intratumoural microbiota: a new frontier in cancer development and therapy
    Yaqi Cao et al, 2024, Sig Transduct Target Ther CrossRef
  78. Cervical Cancer T-Cell Immune Response and Therapeutic Progress
    润生 周, 2024, ACM CrossRef
  79. Transcriptomic profiling of peripheral blood cells in HPV‐associated carcinoma patients receiving combined valproic acid and avelumab
    Najmeh Bozorgmehr et al, 2023, Molecular Oncology CrossRef
  80. Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances
    Soledad Iseas et al, 2024, Mol Diagn Ther CrossRef
  81. Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer
    Sung Wan Kang et al, 2024, PLoS ONE CrossRef
  82. Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis
    Roxana Schwab et al, 2024, Front. Oncol. CrossRef
  83. High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
    Irene Lo Cigno et al, 2024, Journal of Medical Virology CrossRef
  84. The emerging role of human papillomavirus in lung cancer
    Dey Parama et al, 2024, Life Sciences CrossRef
  85. Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance
    Thejus Jayakrishnan et al, 2024, Curr Oncol Rep CrossRef
  86. Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome: A systematic review
    Seth‐Frerich Fobian et al, 2024, Journal of Medical Virology CrossRef
  87. The Effects of Gynecological Tumor Irradiation on the Immune System
    Jesus Romero Fernandez et al, 2024, Cancers CrossRef
  88. Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies
    Ziyao Lu et al, 2024, Cancers CrossRef
  89. Anal Squamous Cell Carcinoma: From Standard Treatment to Personalized Therapy
    Mustafa M. Basree et al, 2024, ARO CrossRef
  90. Drugs and drug targets for the treatment of HPV-positive cervical cancer
    Carly A. Burmeister et al, 2025, Tumour Virus Research CrossRef
  91. The Display between HPV Infection and Host Immunity in Cervical Cancer
    Yuanyuan Gu et al, 2024, Front. Biosci. (Landmark Ed) CrossRef